A European alternative-protein accelerator opens its second Fast-track to Impact cohort

The full briefing covers the named actor, the budget envelope, the timing of the procurement window, and the specific evidence linking the signal to upstream policy decisions.

Subscribers also see the analyst’s take on which adjacent buyers are likely to follow, and which suppliers have already positioned for the work.

• What changed this week
• Why it matters now
• What to watch over the next 1–6 months

Related open opportunities are listed alongside the briefing for Pro subscribers, with named buyers and direct links to apply.